ORMP Profile
Oramed Pharmaceuticals Inc. is a biopharmaceutical company specializing in the research and development of innovative treatments for diabetes and other chronic diseases. The company's primary focus is on advancing oral delivery systems for polypeptide drugs, aiming to provide more convenient and effective treatment options for patients. Oramed's proprietary technology seeks to revolutionize the administration of complex peptides, which traditionally require injection, by developing oral capsules or pills.
The company's flagship product, ORMD-0801, is an oral insulin capsule designed for the treatment of Type 2 diabetes. Having successfully completed Phase II clinical trials, ORMD-0801 represents a significant advancement in non-injection-based insulin delivery, offering potential benefits in patient compliance and quality of life. Oramed also develops ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease, reflecting the company's commitment to addressing diverse and challenging medical conditions.
In addition to ORMD-0801, Oramed is advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule. This product has completed Phase I clinical trials and is targeted at treating Type 2 diabetes. GLP-1 therapies are known for their efficacy in managing blood glucose levels and aiding in weight management, and Oramed's oral formulation aims to offer the same benefits in a more patient-friendly format.
Founded in 2002 and headquartered in New York, Oramed Pharmaceuticals Inc. is at the forefront of developing oral therapeutic solutions for diabetes and other serious health conditions. The company's innovative approach to drug delivery and its focus on enhancing patient experience underscore its role as a key player in the biopharmaceutical industry. Oramed continues to advance its research and clinical programs with the goal of bringing transformative therapies to the market.
|
